Workflow
Biopharmaceuticals
icon
搜索文档
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
Globenewswire· 2025-08-01 01:50
公司动态 - 公司参与虚拟投资者“这意味着什么”环节 [1] - 公司总裁兼首席执行官兼董事Marc Hertz博士讨论正在进行的特发性肺纤维化2a期研究6周中期生物标志物数据 [2] 公司概况 - 公司是临床阶段生物制药公司,专注改变炎症、纤维化和自身免疫性疾病治疗方式 [3] - 公司疗法旨在靶向自然杀伤T细胞活性,中断疾病进展并恢复免疫系统平衡 [3] - 公司主要项目GRI - 0621是iNKT细胞活性抑制剂,正开发为治疗特发性肺纤维化的新型口服疗法 [3] - 公司正在开发用于治疗系统性红斑狼疮的新型2型多样NKT激动剂管线 [3] - 公司拥有超500种专有化合物库,有能力推动管线增长 [3] 投资者联系方式 - 投资者联系JTC Team, LLC的Jenene Thomas,电话(908) 824 - 0775,邮箱GRI@jtcir.com [4]
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
MarketBeat· 2025-08-01 01:23
业绩表现 - 公司2025年第二季度全球净收入达1542亿美元 超出预期的1493亿美元 [1] - 每股收益297美元 较预期的291美元高出2% [1] - 公司上调全年每股收益指引至1188-1208美元区间 高于此前1167-1187美元的预测 [6] 产品组合 - 免疫学产品组合贡献763亿美元净收入 占季度总收入的近50% [5] - Humira净收入同比下降581%至118亿美元 但Skyrizi和Rinvoq分别同比增长618%和418%至442亿和202亿美元 [5] - 公司整体免疫学业务收入同比增长68% [5] 战略发展 - 公司以21亿美元收购临床阶段企业Capstan Therapeutics 强化免疫学管线 [9][10] - 正洽谈收购价值约10亿美元的Gilgamesh Pharmaceuticals 布局下一代迷幻药治疗领域 [10][11] 财务指标 - 股价当前为1954美元 日内上涨31% 52周区间为16381-21866美元 [2] - 股息收益率达336% 已连续53年提高股息 [3] - 市盈率为8341倍 目标价平均为21129美元 [2][8] 市场表现 - 股价正测试195-200美元的关键阻力位 近期突破50日移动均线 [12] - 分析师给予12个月平均目标价21129美元 潜在上涨空间88% [8][13]
Press release: Online availability of Sanofi’s half-year financial report for 2025
Globenewswire· 2025-08-01 00:20
Online availability of Sanofi’s half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K. This document may be found on the company’s corporate website: www.sanofi.com and downloaded from the “Investors” page, under the heading “Re ...
Apellis(APLS) - 2025 Q2 - Earnings Call Transcript
2025-07-31 21:32
Apellis Pharmaceuticals (APLS) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Company ParticipantsTracy Vineis - VP - CommunicationsCedric Francois - Co-Founder, President & CEOTimothy Sullivan - CFOCaroline Baumal - Chief Medical OfficerDavid Acheson - EVP & Head - Global CommercialJonathan Miller - MD - Biotech & Pharma Equity ResearchYigal Nochomovitz - DirectorShrunatra Mishra - AssociateTimur Ivannikov - Research Associate - BiotechnologyKatherine Wang - Equity AssociateDivya Rao - Vice PresidentAnnab ...
Apellis(APLS) - 2025 Q2 - Earnings Call Transcript
2025-07-31 21:30
Apellis Pharmaceuticals (APLS) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good day, and welcome to the Second Quarter twenty twenty five Apellis Pharmaceuticals Inc. Earnings conference call. At this time, all participants are in a listen only mode. After the speaker presentation, there will be a question and answer session. Please be advised that today's conference is being recorded.I would now like to hand the conference over to your speaker, Tracy Venice, Vice President of Communications. Pl ...
ADR Ratio Change Effective
Globenewswire· 2025-07-31 21:30
文章核心观点 - 临床阶段生物制药公司Biodexa Pharmaceuticals PLC宣布美国存托凭证(ADR)比率变更于2025年7月31日开盘生效,变更后1份ADR代表10万股普通股,对ADR持有人而言相当于1比10的反向ADR拆分,发行普通股数量不变,变更后有619,523份ADR流通 [2][3][4] 分组1:ADR比率变更信息 - 公司宣布此前公布的ADR比率变更生效,从1份ADR代表1万普通股变为代表10万普通股 [2] - 比率变更于2025年7月31日美国东部时间开盘生效 [2] - 对ADR持有人来说,比率变更效果等同于1比10的反向ADR拆分 [3] - 每10份原ADR自动换为1份新ADR,原ADR取消,新ADR由公司ADR项目存托银行摩根大通银行发行 [3] 分组2:公司股份数据 - 公司发行普通股数量不受此次变更影响,截至公告发布日为61,952,308,922股 [4] - 比率变更后,流通ADR数量为619,523份 [4]
Bristol-Myers Squibb(BMY) - 2025 Q2 - Earnings Call Transcript
2025-07-31 21:02
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Company ParticipantsChuck Triano - SVP & Head of Investor RelationsChris Boerner - Board Chair & CEODavid Elkins - EVP & CFOGeoff Meacham - Managing DirectorSamit Hirawat - EVP, Chief Medical Officer & Head of DevelopmentAdam Lenkowsky - EVP & Chief Commercialization OfficerChris Schott - Managing DirectorLuisa Hector - Head of Global Pharma Equity ResearchDavid Risinger - Senior Managing Director, BiopharmaAkash Tewari - Glo ...
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
Globenewswire· 2025-07-31 20:45
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needs Inflammatory Bowel Disease is a large and growing market opportunity in China, with forecasts approaching $1B in total revenues by 2030 Carlsbad, CA, July 31, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company ...
Amicus Therapeutics(FOLD) - 2025 Q2 - Earnings Call Presentation
2025-07-31 20:30
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Q2 2025 Results Conference Call & Webcast July 31, 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the prospects and timing of the potential regulatory and pricing approval of our products, commercialization plans, manufacturing and supply plans, financing plans, the collaboration with Dimerix, and the projected revenues and cash posit ...
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
Globenewswire· 2025-07-31 19:45
Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with intermittent dosing schedule; observed clinical activity warrants exploration of potential development opportunities in other cancer types NXP900 successfully completed a clinical drug-drug interaction (DDI) study in healthy volunteers and the Phase 1a dose escala ...